Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis

Moxifloxacin is currently recommended at a dose of 7.5-10 mg/kg for children with multidrug-resistant (MDR) tuberculosis, but pharmacokinetic and long-term safety data of moxifloxacin in children with tuberculosis are lacking. An area under the curve (AUC) of 40-60 µg × h/mL following an oral moxifl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases Jg. 60; H. 4; S. 549
Hauptverfasser:	Thee, Stephanie, Garcia-Prats, Anthony J, Draper, Heather R, McIlleron, Helen M, Wiesner, Lubbe, Castel, Sandra, Schaaf, H Simon, Hesseling, Anneke C
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 15.02.2015
Schlagworte:	Adolescent Antibiotics, Antitubercular - administration & dosage Antibiotics, Antitubercular - adverse effects Antibiotics, Antitubercular - blood Antibiotics, Antitubercular - pharmacokinetics Area Under Curve Child Drug Tolerance Female Fluoroquinolones - administration & dosage Fluoroquinolones - adverse effects Fluoroquinolones - blood Fluoroquinolones - pharmacokinetics Half-Life HIV Infections - complications Humans Male Prospective Studies South Africa Tuberculosis, Multidrug-Resistant - complications Tuberculosis, Multidrug-Resistant - drug therapy South Africa children moxifloxacin toxicity MDR tuberculosis moxifloxacin pharmacokinetics
ISSN:	1537-6591, 1537-6591
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!